Clinical Trial Update: Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the combination of Metformin with EGFR tyrosine kinase inhibitors for treating patients with Non-Small Cell Lung Cancer t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGFR Tyrosine Kinase Inhibitors (EGFR tyrosine kinase inhibitor)
• metformin (metformin)

Snippet

Sponsor: Instituto Nacional de Cancerologia de Mexico | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: RECRUITING